Skip to main content

Advertisement

SpringerLink
Log in

Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) are new therapeutic targets in cancer immunotherapy. The aim of this study was to investigate the clinicopathological characteristics of PD-1 and PD-L1 expression in extranodal natural killer/T‑cell lymphoma, nasal type (ENKTL). We performed PD-1 and PD-L1 immunostaining in 79 ENKTL biopsy samples and retrospectively analyzed medical records of all 79 patients from four tertiary referral hospitals. The expression of PD-1 and PD-L1 by tumor cells and/or infiltrating immune cells was evaluated. The expression rates of PD-L1 in tumor cells and infiltrating immune cells were 79.7 and 78.5 %, respectively, whereas PD-1 in tumor cells and infiltrating immune cells were 1.3 and 11.4 %. The PD-L1 positivity in tumor cells and infiltrating immune cells was significantly associated with low international prognostic index (IPI) (P = 0.044 and 0.037, respectively). Patients with normal range of serum lactate dehydrogenase demonstrated a significantly higher PD-L1 positivity in tumor cells (P = 0.020). PD-L1-positive patients had a trend toward better overall survival compared with that in patients with PD-L1-negative in tumor cells and infiltrating immune cells (P = 0.498 and 0.435, respectively). The expression rate of PD-L1 was up to 79.7 % in ENKTL, while PD-1 expression rate was very low. This is the first report describing the clinicopathological features and survival outcome according to expression of PD-1 and PD-L1 in ENKTL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Huh J (2012) Epidemiologic overview of malignant lymphoma. Korean J Hematol 47(2):92–104

    Article  PubMed  PubMed Central  Google Scholar 

  2. Suh C, Kim WS, Kim JS, Park B-B (2013) Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. Blood Res 48(3):171–177

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jaffe ES (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program: 523-531. doi:10.1182/asheducation-2009.1.523

  4. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ (2013) PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research 19(13):3462–3473. doi:10.1158/1078-0432.ccr-13-0855

    Article  CAS  Google Scholar 

  5. Hamid O, Carvajal RD (2013) Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert opinion on biological therapy 13(6):847–861. doi:10.1517/14712598.2013.770836

    Article  CAS  PubMed  Google Scholar 

  6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine 366(26):2443–2454. doi:10.1056/NEJMoa1200690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. New England Journal of Medicine 372(4):311–319. doi:10.1056/NEJMoa1411087

    Article  PubMed  Google Scholar 

  8. Kim SJ (2015) Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea. Blood Res 50(4):187–188. doi:10.5045/br.2015.50.4.187

    Article  PubMed  PubMed Central  Google Scholar 

  9. A predictive model for aggressive non-Hodgkin’s lymphoma (1993) The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. The New England journal of medicine 329(14):987–994. doi:10.1056/nejm199309303291402

    Article  Google Scholar 

  10. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin D-Y, Kim JS, Jeong SH, Yang D-H, Jo J-C, Lee G-W, Choi CW, Lee W-S, Chen T-Y, Kim K, Jung S-H, Murayama T, Oki Y, Advani R, d’Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin T-Y, Kim WS A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. The Lancet Oncology 17 (3):389-400. doi:10.1016/S1470-2045(15)00533-1

  11. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. International immunology 8(5):765–772

    Article  CAS  PubMed  Google Scholar 

  12. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM (2011) Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clinical cancer research : an official journal of the American Association for Cancer Research 17(13):4232–4244. doi:10.1158/1078-0432.ccr-10-2660

    Article  CAS  Google Scholar 

  13. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) A review of human carcinogens—Part B: biological agents. The Lancet Oncology 10(4):321–322

    Article  PubMed  Google Scholar 

  14. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O’Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 18(6):1611–1618. doi:10.1158/1078-0432.ccr-11-1942

    Article  CAS  Google Scholar 

  15. Paydas S, Bagir E, Seydaoglu G, Ercolak V, Ergin M (2015) Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Annals of hematology 94(9):1545–1552. doi:10.1007/s00277-015-2403-2

    Article  CAS  PubMed  Google Scholar 

  16. Koh YW, Jeon YK, Yoon DH, Suh C, Huh J (2015) Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. doi:10.1007/s13277-015-4622-5

    Google Scholar 

  17. Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, Maestre L, Pileri S, Hansmann ML, Piris MA, Mason DY, Marafioti T (2007) Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 92(8):1059–1066

    Article  CAS  PubMed  Google Scholar 

  18. Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A (2005) CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Human pathology 36(7):784–791. doi:10.1016/j.humpath.2005.05.008

    Article  CAS  PubMed  Google Scholar 

  19. Ree HJ, Kadin ME, Kikuchi M, Ko YH, Suzumiya J, Go JH (1999) Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: heterogeneity of intrafollicular T-cells and their altered distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma. Human pathology 30(4):403–411

    Article  CAS  PubMed  Google Scholar 

  20. Huang B, Chen L, Bao C, Sun C, Li J, Wang L, Zhang X (2015) The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. OncoTargets and therapy 8:2617–2625. doi:10.2147/ott.s91025

    PubMed  PubMed Central  Google Scholar 

  21. Wu P, Wu D, Li L, Chai Y, Huang J (2015) PD-L1 and survival in solid tumors: a meta-analysis. PloS one 10(6), e0131403. doi:10.1371/journal.pone.0131403

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hawkes EA, Grigg A, Chong G (2015) Programmed cell death-1 inhibition in lymphoma. The Lancet Oncology 16(5):e234–245. doi:10.1016/s1470-2045(15)70103-8

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded by Ulsan University Hospital (Biomedical Research Center Promotion Fund; Grant no. 2015-1).

Conflicts of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea

    Jae-Cheol Jo, Yunsuk Choi & Hawk Kim

  2. Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Ulsan, Dong-gu, 682-714, South Korea

    Misung Kim & Hee Jeong Cha

  3. Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, South Korea

    Hyun-Jung Kim

  4. Department of Pathology, Seoul National University Boramae Hospital, Seoul, South Korea

    Ji Eun Kim

  5. Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Seoung Wan Chae

Authors
  1. Jae-Cheol Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Misung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yunsuk Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyun-Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ji Eun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seoung Wan Chae
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hawk Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hee Jeong Cha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hee Jeong Cha.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 61 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jo, JC., Kim, M., Choi, Y. et al. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 96, 25–31 (2017). https://doi.org/10.1007/s00277-016-2818-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2818-4

Keywords

Search

Navigation